Andrey V. Gordeev

Andrey V. Gordeev

Auto-generated profile, based on publicly available information

Andrey V. Gordeev

V.A. Nasonova Research Institute of Rheumatology

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2021 in Modern Rheumatology Journal
Verified
Journal Article
Open access
PDF file
AGA. V. Gordeev
A. V. Gordeev
YOYu. A. Olyunin
Yu. A. Olyunin
EGE. A. Galushko
E. A. Galushko
EZE. G. Zotkin
E. G. Zotkin
ALAleksandr M Lila
Aleksandr M Lila
ЮОЮ. А. Олюнин
Ю. А. Олюнин
The widespread introduction into clinical practice of modern approaches to the treatment of rheumatoid arthritis (RA), the rational use of traditional and targeted antirheumatic drugs can effectively suppress inflammatory activity, restrain the progression of the disease and improve the quality of life of patients. At the same time, in some patients, even after the repeated change of targeted drugs, it is not possible to achieve the target level of RA activity. Serious difficulties arising in the management of such patients raised the question of identifying a special variant of the disease – difficult-to-treat (D2T) RA. The presence of various variants of D2T RA and the need to use a personalized approach to therapy justify the creation of special recommendations for the management of this category of patients. The first step in preparing these recommendations was the definition of D2T RA recently presented by the EULAR working group. It includes three criteria: 1) insufficient effectiveness of the therapy; 2) the presence of an active symptomatic disease; 3) clinical perception.

17 June 2022 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
EGElena A. Galushko
Elena A. Galushko
AGAndrey V. Gordeev
Andrey V. Gordeev
EMElena V. Matyanova
Elena V. Matyanova
YOYury A. Olyunin
Yury A. Olyunin
ENEvgeny L. Nasonov
Evgeny L. Nasonov
ОАОлюнин Юрий Александрович
Олюнин Юрий Александрович
Aim. To compare the features of the course of the disease and the therapy in rheumatoid arthritis (RA) patients who meet the criteria of difficult-to-treat RA (D2T). Materials and methods. The study included 505 RA patients (ACR/EULAR 2010). Rheumatologist experts discussed all patients, since the treatment of RA ware perceived as problematic and/or insufficient. All patients had at least one of the following signs: the activity of the disease is no lower than moderate; the inability to reduce the dose of glucocorticoids to low; rapid radiological progression; RA symptoms causing a decrease in quality of life. The D2T group included 35 patients with true inefficiency or intolerance of two or more of bDMARDs/tsDMARDs of different mechanism of action. The control group (K) included patients with RA who already had experience of taking at least one class of bDMARDs/tsDMARDs (n=291). Results. On average, every 15 patients (7%) with RA met the EULAR criteria for D2T. The median age of patients in the D2T group was 45 years, which is less than in K (Me 54 [43; 62] years; p=0.046). The duration of RA in both groups was comparable. The severity of articular destruction in D2T was higher than in K (stage IV in 40% and 23%, respectively). Positivity for the RF and ACPA in D2T was less common than in K (60% and 85.9%; 60% and 76.6%, respectively). The presence of systemic manifestations of RA was more typical for K than for D2T (28.6% and 63%, p=0.0001). In the group of D2T patients, the number of previously taken DMARDs was higher than in K (p=0.002). Methotrexate was more often prescribed as the first DMARDs in both groups (in 62.9 and 65.7%, respectively). Initiation of bDMARDs/tsDMARDs therapy in D2T was more often performed by TNF-a inhibitors (OR 2.8; p=0.003) and co-stimulation blocker abatacept (OR 4.6; p=0.004), and in control by B-cell inhibitor rituximab (OR 6.9; p0.0001). Conclusion. The results of this study suggest that in Russia, as well as abroad, the principle of RA treatment treat to target has not yet become widespread, and the development of adequate therapy takes too much time.

22 April 2023 in Modern Rheumatology Journal
Verified
Journal Article
Open access
PDF file
AGA. V. Gordeev
A. V. Gordeev
YOYu. A. Olyunin
Yu. A. Olyunin
EGE. A. Galushko
E. A. Galushko
EZE. G. Zotkin
E. G. Zotkin
ALA. M. Lila
A. M. Lila
ЮОЮ. А. Олюнин
Ю. А. Олюнин
The problem of comorbidity is widely discussed in modern medical literature. Its role in rheumatic diseases is of particular interest due to their multifactorial nature and the involvement of a wide range of pathogenetic mechanisms. For many years, researchers around the world have noted correlations between the presence of active autoimmune disorders and the complicated course of cardiovascular diseases. A deeper understanding of the pathogenetic mechanisms at the present stage of development of rheumatology allows us to take a fresh look at the relationship between atherosclerosis and rheumatoid arthritis. The definition of multimorbidity developed in recent years and the results of recent scientific studies may contribute to a more correct choice of tactics for managing patients with a combination of these two diseases.

6 May 2022 in Modern Rheumatology Journal
Verified
Journal Article
Open access
PDF file
AGA. V. Gordeev
A. V. Gordeev
EME. V. Matyanova
E. V. Matyanova
YOYu. A. Olyunin
Yu. A. Olyunin
EGE. A. Galushko
E. A. Galushko
EZE. G. Zotkin
E. G. Zotkin
ЮОЮ. А. Олюнин
Ю. А. Олюнин
Objective: to compare the course of the disease and therapy in rheumatoid arthritis (RA) patients who meet and do not meet the criteria for difficult- to-treat RA (D2T).Patients and methods. The study included RA patients who met the 2010 ACR/EULAR criteria and who were hospitalized in the V.A. Nasonova Research Institute of Rheumatology from March to October 2021. All patients underwent a conventional clinical and laboratory examination, radiography of the hands and distal feet, and the radiological stage of RA according to Steinbroker was assessed. To determine the inflammatory activity, the DAS28-ESR and DAS28-CRP indices were calculated.Results and discussion. The study included 303 patients with RA, 25 (8.4%) of them had D2T RA. The duration of RA in the D2T group was significantly longer than in other patients (15.9±11.8 and 11.9±9 years, respectively; p=0.04). X-ray changes in the joints in D2T were more pronounced. Patients with D2T had higher inflammatory activity at the time of hospitalization than patients who had continued prior therapy with biologic/targeted synthetic DMARDs. The dose of glucocorticoids (GC) in patients with D2T RA was higher compared to patients of other groups: on average 8.3±5.1 and 6.4±2.9 mg/day, respectively (p=0.02).Conclusion. The results of this study suggest that in Russia, as well as abroad, the treat-to-target principle has not yet become widespread, and the selection of adequate therapy takes too much time. At the same time, Russian rheumatologists primarily use GC to suppress inflammatory activity. The introduction of modern recommendations for the management of patients with RA into routine clinical practice, could possibly restrain the formation of D2T RA.

19 September 2019 in Modern Rheumatology Journal
Verified
Journal Article
Open access
PDF file
ZMZ. Yu. Mutovina
Z. Yu. Mutovina
AZAlena I. Zagrebneva
Alena I. Zagrebneva
EGE. A. Galushko
E. A. Galushko
AGA. V. Gordeev
A. V. Gordeev
Кардиоренальный синдром у больных ревматоидным артритом

16 July 2023 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
AGAndrey V. Gordeev
Andrey V. Gordeev
EMElena V. Matyanova
Elena V. Matyanova
EGElena A. Galushko
Elena A. Galushko
Background. In Russia, as well as throughout the world, the use of glucocorticoids (GC) in the treatment of rheumatoid arthritis (RA) is widespread, often going beyond the recommendations for both duration and dose regimen, which makes it relevant to study the long-term consequences of such a wrong (EULAR, 2022) use of GC in RA therapy. Materials and methods. Of 1143 patients with active RA (ACR/EULAR 2010), two groups were formed: A (n=782) RA patients with more than 6 months of experience with systemic GC; group B (n=245) no experience of taking GC. The cumulative disease index (CIRS) was used to assess the comorbidity profile. Results. Patients in group A were older (p0.0001), with a longer duration of RA (p=0.0004) and more often with IV radiological stage (p=0.02). With comparable (DAS28) RA activity, the D2T variant of RA was more often detected in them (p=0.036). RA therapy in group A was characterized by a large number of used disease-modifying anti-rheumatic drugs (p=0.0003), more frequent development of methotrexate-induced hepatitis (p=0.03). In group A, the time interval between the onset of RA and the initiation of biological therapy was longer (p=0.0001) and directly correlated with the duration of GC therapy (Rs=0.38) with a comparable qualitative structure of the used b/tsDMARDs. In the same group, tuberculosis, hypertension, chronic kidney disease, cataract and osteoporosis (p0.05) and its complications were diagnosed significantly more often with a comparable frequency of cardiovascular disease, diabetes, and gastrointestinal lesions. In group A, a higher CIRS multimorbidity index was detected, and the CIRS severity index was lower than in group B (p0.05). Conclusion. Long-term use of GC did not lead to a decrease in disease activity, inhibition of radiographic progression, delayed the timely administration of b/tsDMARDS and was accompanied by an increase in the multimorbid load.